Syntopix Group Plc – Product Pipeline Review – H2 2011

Date: November 1, 2011
Pages: 52
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S12011668F7EN
Leaflet:

Download PDF Leaflet

Syntopix Group Plc – Product Pipeline Review – H2 2011
Syntopix Group Plc – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Syntopix Group Plc - Product Pipeline Review - H2 2011” provides data on the Syntopix Group Plc’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Syntopix Group Plc’s corporate website, SEC filings, investor presentations and featured press releases, both from Syntopix Group Plc and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Syntopix Group Plc - Brief Syntopix Group Plc overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Syntopix Group Plc human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Syntopix Group Plc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Syntopix Group Plc’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Syntopix Group Plc’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Syntopix Group Plc in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Syntopix Group Plc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Syntopix Group Plc.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Syntopix Group Plc and identify potential opportunities in those areas.
Syntopix Group Plc Snapshot
Syntopix Group Plc Overview
Key Information
Key Facts
Syntopix Group Plc – Research and Development Overview
Key Therapeutic Areas
Syntopix Group Plc – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Syntopix Group Plc – Pipeline Products Glance
Syntopix Group Plc Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Syntopix Group Plc–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Syntopix Group Plc – Drug Profiles
SYN 0017
  Product Description
  Mechanism of Action
  R&D Progress
SYN 0096
  Product Description
  Mechanism of Action
  R&D Progress
SYN 0126
  Product Description
  Mechanism of Action
  R&D Progress
SYN 0126 + SYN 0040
  Product Description
  Mechanism of Action
  R&D Progress
SYN 0126 + SYN 0091
  Product Description
  Mechanism of Action
  R&D Progress
SYN 0126 + SYN 0854 + SYN 0040
  Product Description
  Mechanism of Action
  R&D Progress
SYN 0854
  Product Description
  Mechanism of Action
  R&D Progress
SYN 1093
  Product Description
  Mechanism of Action
  R&D Progress
SYN 1113
  Product Description
  Mechanism of Action
  R&D Progress
SYN 1163
  Product Description
  Mechanism of Action
  R&D Progress
Syntopix Group Plc – Pipeline Analysis
Syntopix Group Plc – Pipeline Products by Therapeutic Class
Syntopix Group Plc – Pipeline Products by Route of Administration
Syntopix Group Plc – Recent Pipeline Updates
Syntopix Group Plc - Dormant Projects
Syntopix Group Plc – Company Statement
Syntopix Group Plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Apr 27, 2011: Syntopix Provides Update On SYN1113
Feb 26, 2008: Syntopix Group Plc Announces Positive Acne SYN 0126 And SYN 0091 Formula Study Results
Feb 26, 2008: Syntopix Group Plc Announces Positive Acne SYN 0126 Formula Phase II Study Results
Financial Deals Landscape
Syntopix Group Plc, Deals Summary
Syntopix Group Plc, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Syntopix Group Secures $0.95 Million In Venture Financing
Syntopix Group Secures $0.33 Million In Venture Financing
Partnerships
Syntopix Enters Into Research Agreement With Beiersdorf
Syntopix Enters Into Co-Development Agreement With Sinclair Pharma
Syntopix Group Enters Into Co-Development Agreement With The Procter & Gamble
Equity Offering
Syntopix Group Announces Private Placement Of $3.29 Million
Syntopix Completes Private Placement Of $3 Million
Syntopix Completes Private Placement Of $3 Million
Syntopix Group Completes Initial Public Offering Of $7 Million
Acquisition
Syntopix Group To Acquire Leeds Skin Centre
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Syntopix Group Plc – Pipeline by Therapy Area and Indication, H2 2011
Syntopix Group Plc – Pipeline by Stage of Development, H2 2011
Syntopix Group Plc – Monotherapy Products in Pipeline, H2 2011
Syntopix Group Plc – Combination Treatment Modalities in Pipeline, H2 2011
Syntopix Group Plc - Phase II, H2 2011
Syntopix Group Plc - Pipeline By Therapeutic Class, H2 2011
Syntopix Group Plc – Pipeline By Route of Administration, H2 2011
Syntopix Group Plc – Recent Pipeline Updates, H2 2011
Syntopix Group Plc - Dormant Developmental Projects, 2010
Syntopix Group Plc, Subsidiaries
Syntopix Group Plc, Deals Summary
Syntopix Group Secures $0.95 Million In Venture Financing
Syntopix Group Secures $0.33 Million In Venture Financing
Syntopix Enters Into Research Agreement With Beiersdorf
Syntopix Enters Into Co-Development Agreement With Sinclair Pharma
Syntopix Group Enters Into Co-Development Agreement With The Procter & Gamble
Syntopix Group Announces Private Placement Of $3.29 Million
Syntopix Completes Private Placement Of $3 Million
Syntopix Completes Private Placement Of $3 Million
Syntopix Group Completes Initial Public Offering Of $7 Million
Syntopix Group To Acquire Leeds Skin Centre

LIST OF FIGURES

Syntopix Group Plc – Pipeline by Therapy Area and Indication, H2 2011
Syntopix Group Plc – Pipeline by Stage of Development, H2 2011
Syntopix Group Plc – Monotherapy Products in Pipeline, H2 2011
Syntopix Group Plc – Combination Treatment Modalities in Pipeline, H2 2011
Syntopix Group Plc – Pipeline By Therapeutic Class, H2 2011
Syntopix Group Plc – Pipeline By Route of Administration, H2 2011

Ask Your Question

Syntopix Group Plc – Product Pipeline Review – H2 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: